CONVERT II
Are You Eligible?This clinical trial is designed to investigate the safety and effectiveness of the AeriSeal System to close open-air channels and stop air flow between your lung compartments, for patients with severe emphysema.
Research Objectives
Status
Recruitment
Total participants required
Study location
Study type
Patient group
About this clinical trial
An evaluation of the AeriSeal System for CONVERTing collateral ventilation status in patients with severe emphysema.
The trial will evaluate lung function changes, hyperinflation (trapped air causing the lungs to become too large), quality of life, and adverse events after the closure of the air channels with the AeriSeal System, followed by the implantation of the Zephyr Valve to achieve bronchoscopic lung volume reduction.
Eligibility
- Subject is aged ≥ 22 and ≤ 80 years at the time of the ICF signature date.
- Subject has completed a documented pulmonary rehabilitation (in clinic or home-based) program within 6 months prior to Baseline.
- Subject has stopped smoking for at least 8 weeks prior to the ICF signature date .
- Subject has heterogenous emphysema
Lead investigator
- Dr Farzad Bashirzadeh
Clinical trial coordinators
- Chris Henderson
- Bronwen Field
- Marie-Louise Oegema
Technical title
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema: The CONVERT II Trial.
Register your interest
If you would like more information about this clinical trial, please complete the contact form below.